Recent Developments in the Drug Treatment of Parkinson’s Disease
Abstract Parkinson’s disease (PD) is a common neurodegenerative disorder caused by a spread of misfolded α-synuclein and ascending neuronal degeneration…
Werner Poewe
Long-term safety and efficacy of open-label nabilone on sleep and pain in Parkinson´s Disease
Abstract The synthetic tetrahydrocannabinol-analog nabilone improved non-motor symptoms (NMS) in Parkinson’s disease (PD) patients in a placebo-controlled, double-blind, parallel-group, randomized…
Pharmacological Treatment of Tremor in Parkinson’s Disease Revisited
Abstract The pathophysiology of Parkinson’s disease (PD) tremor remains incompletely understood and there is a lack of clinical trials specifically…
Effects of Nabilone on Sleep Outcomes in Patients with Parkinson’s Disease: A Post‐hoc Analysis of NMS‐Nab Study
Abstract Background: The synthetic tetrahydrocannabinol analogue nabilone improved overall non‐motor symptom (NMS) burden in Parkinson’s disease (PD) patients in comparison…
Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study
Abstract The topic of the therapeutic use of cannabinoids in Parkinson’s disease (PD) is broadly discussed and frequently comes up…
Non‐Motor Symptoms in Parkinson’s Disease are Reduced by Nabilone
Abstract Objective: The objective of this study was to assess the efficacy and safety of nabilone, a synthetic tetrahydrocannabinol analogue,…
Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study)
Abstract Although open-label observations report a positive effect of cannabinoids on non-motor symptoms (NMS) in Parkinson’s disease (PD) patients, these…